Sarepta Therapeutics (SRPT) Posts Smaller Q3 Loss, Sees Submitting Eteplirsen NDA in Mid-2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Sarepta Therapeutics (SRPT) Posts Smaller Q3 Loss, Sees Submitting Eteplirsen NDA in Mid-2015

Needham & Company Maintains Bullish View on Sarepta Therapeutic (SRPT) Following Results and Eteplirsen Regulatory Update

November 6, 2014 11:35 AM EST

Needham & Company analyst Chad Messer reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q3 results and an Eteplirsen regulatory update.

Messer comments, "Sarepta remains on track to file an NDA for eteplirsen in Duchenne's muscular dystrophy... More